Recommendation
The FTC and FDA should clarify and improve guidelines for telehealth advertisements offering controlled substances such as ADHD medication.
Details
While many health care providers began offering telehealth services during the pandemic, or expanded existing operations, there have also been a number of new telehealth companies that have used pandemic-era telehealth policies to offer prescription stimulants to individuals even when they are not medically necessary. Individuals seeking these drugs can easily find online providers that offer remote medical treatment for ADHD, making it possible to obtain prescription stimulants with only a few clicks. These providers not only endanger the health and safety of individuals who obtain these drugs for non-medical purposes, but also threaten to delegitimize valid uses of telehealth services for mental health. The Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) should update regulatory guidelines to prevent telehealth platforms from advertising pharmaceutical medications for common concerns without disclosing side effects, as has happened in ads claiming ADHD medication provides patients with a “quiet mind” or suggesting it can treat job anxiety.
Keep reading:
▪ Morgan Stevens, “Click Here for Adderall: Fixing Telehealth Advertising and Services To Prevent Stimulant Misuse” (ITIF Center for Data Innovation, December 2022), https://itif.org/publications/2022/12/05/fixing-telehealth-advertising-and-services-to-prevent-stimulant-misuse/.